Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients With Mucopolysaccharidosis I (MPS I) Being Treated With Aldurazyme® (Laronidase).

NCT00144768 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00144768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients With Mucopolysaccharidosis I (MPS I) Being Treated With Aldurazyme® (Laronidase).
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2004
Completion date
May 31, 2007
Enrollment
25 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hurler's syndrome, hurler-scheie syndrome, mucopolysaccharidosis i, scheie's syndrome